



THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Genflow Biosciences Plc

Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 Development

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), a leading European-based biotechnology company focusing on longevity, is pleased to confirm receipt of the first instalment of €336,467 of the previously announced €4 million non-dilutive grant awarded by the Wallonia Region of Belgium, (see RNS dated 22 October, 2024 [here](#).)

The support package spans a three-year development programme and is aligned with Genflow's existing roadmap for GF-1002 in MASH.

The grant will support the continued development of the Company's lead gene therapy candidate, GF-1002, with further instalments expected to be received in accordance with the agreed milestone and disbursement schedule. The first instalment has been received and will be applied toward eligible project-related activities.

Dr. Eric Leire, CEO of Genflow, commented: "We are pleased to confirm receipt of the first instalment under the €4 million Wallonia Region grant. This initial funding supports the continued advancement of GF-1002 in MASH and strengthens our ability to execute against planned development milestones. We look forward to progressing the programme and receiving subsequent instalments in line with the agreed framework."

Contacts

Genflow Biosciences

Dr Eric Leire, CEO
+32-477-495-881

Harbor Access

Jonathan Paterson, Investor Relations
+1 475 477 9401
Jonathan.Paterson@Harbor-access.com

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts



of a fast-growing aging global population. Genflow's lead compound, GF-1002, delivers a proprietary centenarian variant of the SIRT6 gene. The therapy is currently being evaluated in the Company's randomised, blinded SLAB (Sarcopenia and Longevity in Aged Beagles) study in dogs aged over 10 years, which commenced in March 2025. Preliminary interim results demonstrated improved survival versus control during the dosing period, alongside favourable safety and tolerability and positive trends across functional endpoints including muscle mass preservation, frailty reduction and quality of life. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on [LinkedIn](#) and [X](#).

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict



all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.